Phase 2, Phase 3 Recruiting NIH
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Sites in New York: - South Shore University Hospital — Bay Shore, New York
- New York-Presbyterian/Brooklyn Methodist Hospital — Brooklyn, New York
- NYU Langone Hospital - Brooklyn — Brooklyn, New York
- Roswell Park Cancer Institute — Buffalo, New York
- Sands Cancer Center — Canandaigua, New York
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in New York: - Memorial Sloan Kettering Commack — Commack, New York
- Glens Falls Hospital — Glens Falls, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- State University of New York Upstate Medical University — Syracuse, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in New York: - Research Site — New York, New York
- Research Site — New York, New York
- Research Site — New York, New York
- Research Site — The Bronx, New York
- Research Site — The Bronx, New York
Phase 3 Recruiting Industry
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in New York: - Site 24 — New York, New York
- Site 214 — The Bronx, New York
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in New York: - Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Montefiore Medical Center — The Bronx, New York
- Bronx Veterans Affairs Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in New York: - GSK Investigational Site — New York, New York
- GSK Investigational Site — The Bronx, New York
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in New York: - Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009) — New York, New York
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in New York: - Northwell Health/Center for Advanced Medicine — Lake Success, New York
- NYU Langone Hospital - Long Island — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone — New York, New York
Phase 2 Recruiting Academic/Other
This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…
Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in New York: - Montefiore Medical Center-Einstein Campus — The Bronx, New York
- Montefiore Medical Center - Moses Campus — The Bronx, New York
Phase 2 Recruiting NIH
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from wh…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05904080
Sites in New York: - Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in New York: - Albany Medical Center — Albany, New York
- Montefiore Medical Center - Moses Campus — The Bronx, New York
Phase 2 Recruiting Industry
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types ar…
Sponsor: Vyriad, Inc.
NCT ID: NCT04291105
Sites in New York: - Icahn School of Medicine at Mount Sinai — New York, New York
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in New York: - Columbia University — New York, New York
- NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in New York: - NYU Langone Health — New York, New York
- Icahn School of Medicine At Mount Sinai Prime — New York, New York
- Clinical Research Alliance — Westbury, New York
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…
Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in New York: - Weill Cornell Medicine, Cornell University (site 126) — New York, New York
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Academic/Other
This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04620187
Sites in New York: - Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in New York: - Local Institution - 0006 — New York, New York
- Local Institution - 0002 — New York, New York
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Academic/Other
This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05307939
Sites in New York: - Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) — Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activites) — East White Plains, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) — Rockville Centre, New York
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few …
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06925724
Sites in New York: - Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities) — Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) — Uniondale, New York
Phase 2 Recruiting Academic/Other
This study will test whether limiting standard photon intensity modulated radiation therapy (IMRT) to exclude the oral tongue surgical site can decrease the risk of side effects caused by oral radiation. The researchers will also find out …
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06485778
Sites in New York: - Memorial Sloan Kettering Suffolk - Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
Phase 2 Recruiting Academic/Other
The researchers are doing this study is to find out if lower doses (given in fewer treatments over a shorter period of time) of radiation therapy in combination with standard-of-care chemotherapy is an effective treatment for people with H…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06984861
Sites in New York: - Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) — Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) — Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Uniondale, New York
Phase 1, Phase 2 Recruiting Industry
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination …
Sponsor: Simcha IL-18, Inc.
NCT ID: NCT04787042
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York